Login / Signup

Longitudinal estimation of Plasmodium falciparum prevalence in relation to malaria prevention measures in six sub-Saharan African countries.

Chris DrakeleySalim AbdullaSelidji Todagbe AgnandjiJosé Francisco FernandesPeter KremsnerBertrand LellLudovic MewonoBache Emmanuel BacheMichael Gabriel MihayoOmar JumaMarcel TannerMarc Christian TahitaHalidou TintoSalou DialloPalpouguini LompoUmberto D'AlessandroBernhards OgutuLucas OtienoSolomon OtienoWalter OtienoJanet OyiekoKwaku Poku AsanteDominic Bon-Ereme DeryGeorge AdjeiElisha AdenijiDorcas AtibillaSeth Owusu-AgyeiBrian GreenwoodSamwel GesaseJohn LusinguColine MahendeRobert MongiMethod SegejaSamuel AdjeiTsiri AgbenyegaAlex AgyekumDaniel AnsongJohn Tanko BawaHarry Owusu BoatengLéonard DandaloVeronica EscamillaIrving HoffmanPeter MaenjeFrancis MartinsonTerrell CarterDidier LeboulleuxDavid C KaslowEffua UsufJean-Yves PirçonEdith Roset Bahmanyar
Published in: Malaria journal (2017)
Local PfPR differed substantially between sites and age groups. In children 6 months-4 years old, a significant decrease in prevalence over the 3 years was observed in 4 out of the 8 study sites. Trial registration Clinical Trials.gov identifier: NCT01190202:NCT. GSK Study ID numbers: 114001.
Keyphrases
  • plasmodium falciparum
  • clinical trial
  • signaling pathway
  • phase ii
  • phase iii
  • cross sectional
  • open label